Company profile
ZIVO Bioscience, Inc.
OTC: ZIVO · Healthcare · Biotechnology
#1024 of 1,422 Healthcare companies by revenuetop-decile growth
EA Score
——FH —DQ 54GM —SS 50
v0.1 · 25/100 weight · pillars only
↑ revenue growth (YoY), disclosure history · ↓ return on assets, Altman-Z
Methodology →Revenue TTM
$65.6k
Rev growth YoY (TTM)
-62.5%
Net income (FY)
-$13.4M
Employees
7
as of 2026-08-21
Market cap
$15.4M
as of 2026-08-21
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$157.2k$157.2k2024
Net income-$13.4M-$13.4M2024
Operating income-$13.4M-$13.4M2024
Total assets$1.6M$1.6M2024
Liabilities$2.2M$2.2M2024
Equity-$514.9k-$514.9k2024
Revenue trend
FY2017 – FY2024 · USD
FY17
FY19
FY19
FY20
FY21
FY23
FY23
FY24
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is ZIVO Bioscience, Inc.’s revenue?
ZIVO Bioscience, Inc. booked $157.2k in FY2024 revenue, growing 469% year over year — faster than 94% of Healthcare companies we track, at a -8513.4% net margin.
Peers · Healthcare
InnerScope Hearing Technologies, Inc.——Kalaris Therapeutics Inc30DCurative Biosciences, Inc.——Cannabis Strategic Ventures——Anthera Pharmaceuticals, Inc.——VivoSim Labs, Inc.——Neighbors
Oakland →Key facts
CEOJohn Bernard Payne
SectorHealthcare
IndustryBiotechnology
HeadquartersBloomfield Hills, MI
ExchangeOTC: ZIVO
Employees7
IPO date2003-12-15
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.